Clinical Research in Oncology

Clinical Development Success Rates



The Biotechnology Innovation Organization (BIO) has released the largest ever study of clinical development success rates, with a focus on the advantages of using biomarkers in clinical trials.  


Some of the conclusions: 

  • Clinical trial programs that used selection biomarkers saw an overall likelihood of approval (LOA) from Phase I of 25.9%, compared to 8.4% when no selection biomarkers were used.

  • Oncology drugs were approved the fastest of all 14 disease areas.


Read the study:










Share on Facebook
Share on Linkedin